Interventional Glaucoma

Sustained-release option overcomes limitations of topically administered drops

Research offers guidance on NSAID use, identifies etiologic role of abnormal IOP

Prescription drug costs are a pressing concern for both physicians and patients

With imaging artifacts common, clinicians must be focused on key points

Technology makes great tool, requires extra vigilance with co-existing disease

Studies have shown changes in outflow system structures mimic effects of pilocarpine

Physicians also can focus on treating inflammation and IOP in patients

Common devices differ in hardware, analysis, and display of data

Applying a cautious approach can increase the chance for successful outcomes

Lipid regulation within primary cilia may prove to be a solution for patients

Some finesse may go a long way for physicians to ensure best possible result for patients

Secure closure of the scleral flap a key to avoiding early hypotony

Postoperative complications can have multiple causes and preventative measures

Selective laser trabeculoplasty (SLT) should be offered to patients diagnosed with open-angle glaucoma as a first-line therapy.

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Selective laser trabeculoplasty (SLT) could be an affordable option for glaucoma management, according to Nathan Radcliffe, MD. 

E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant. 

Test your knowledge on MIGS procedures

Differentiating across categories instrumental to establishing accurate value

Surgeons can anticipate flurry of product releases that will drive innovation

Surgeon sheds light on his experiences with variety of innovative surgery options

Project involves development of patient-reported outcome measure